Katie Lapidus advises private and public companies of all stages on a variety of corporate matters including formation, financing activities, corporate governance and securities law compliance. Katie also represents companies and underwriters in initial public offerings and follow-on securities offerings and counsels public companies with respect to SEC reporting obligations.
Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement
November 3, 2023
Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
NewAmsterdam Pharma – $181.6 Million Follow-on Offering
June 6, 2023
Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.
Prelude Therapeutics – $100 Million Follow-on Offering
May 18, 2023
Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.
Olink Holding AB – $116.6 Million Follow-on Offering
January 18, 2023
Cooley advised the underwriters in Olink Holding AB’s $116.6 million follow-on offering. Olink is a company dedicated to working with the scientific community on accelerating proteomics across multiple disease areas to enable new discoveries and improve the lives of patients. Lawyers Eric Blanchard, Charlie Kim, Minkyu Park, Ryan Walker, Katie Lapidus, Megan Taing and Charles York led the Cooley team.